Registry for Migraine - Structural and Functional MRI Before and After Erenumab Treatment

Criteria: Inclusion Criteria:

• Subject has provided informed consent prior to initiation of any study-specificactivities/procedures
• Age greater than or equal to 18 years upon entry into screening
• History of migraine (with or without aura) for greater than or equal to 12 monthsbefore screening according to the International Headache Society (IHS) ClassificationICHD-3 (Headache Classification Committee of the International Headache Society, 2018)based on medical records and/or patient self report
• Greater than or equal to 4 headache days that meet criteria as migraine days per monthon average across the 3 months before screening after baseline period
• Must have demonstrated greater than or equal to 75% compliance in headache diary usageduring baseline period

Exclusion Criteria: Subjects are excluded from the study if any of the following criteria apply: Disease Related

• Greater than 50 years of age at migraine onset
• History of cluster headache or hemiplegic migraine headache
• Inability to differentiate between migraine from other headaches
• The subject is at risk of self-harm or harm to others as evidenced by past suicidalbehaviour
• History or evidence of any other clinically significant disorder, condition or disease (with the exception of those outlined above) that, in the opinion of the investigatorwould pose a risk to subject safety or interfere with the study evaluation, proceduresor completion Prior/Concomitant Therapy
• Previously received erenumab (Aimovig®)
• Received an anti-CGRP monoclonal antibody within 3 months prior to the start of thebaseline period Prior/Concurrent Clinical Study Experience
• Currently receiving treatment in another investigational device or drug study, or lessthan 30 days or 5 half-lives since ending treatment on another investigational deviceor drug study (ies). Other investigational procedures while participating in thisstudy are excluded. Other Exclusions
• Female subjects of childbearing potential with a positive pregnancy test assessed atscreening or day 1 by a urine pregnancy test.
• Female subject is pregnant or breastfeeding or planning to become pregnant orbreastfeed during treatment and for an additional 16 weeks after the last dose ofinvestigational product.
• Female subjects of childbearing potential unwilling to use 1 acceptable method ofeffective contraception during treatment and for an additional 16 weeks after the lastdose of investigational product.
• Evidence of current pregnancy or breastfeeding per subject self-report or medicalrecords
• Subject has known sensitivity to any of the products or components to be administeredduring dosing
• Subject likely to not be available to complete all protocol-required study visits orprocedures, and/or to comply with all required study procedures to the best of thesubject and investigator's knowledge Contraindications to MRI:
• Does not wish to be informed about unexpected MRI findings
• Severe claustrophobia
• Implanted magnetic material including pacemaker, prothesis, metal-clips, etc.
• Insulin pump which cannot be removed
• Magnetic foreign object in the body
• Surgical intervention within 6 weeks prior to MRI